ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
hormone replacement therapy
The following articles have the tag hormone replacement therapy
Debate on HRT for bone risk
DESPITE international and Australian expert recommendations to use hormone replacement therapy to prevent osteoporosis-related fractures, it is unlikely to be endorsed as first-line therapy in Australia, the RACGP says.
Expert flags oestrogen-only HRT safer than combination
CANCER Council chief executive Professor Ian Olver has sparked controversy by suggesting that using unopposed oestrogen for hormone replacement therapy (HRT) is associated with a lower overall cancer risk than combination therapy, even in menopausal women who have not had a hysterectomy.
HRT no CVD benefit, review confirms
NEW evidence confirms the failure of HRT to offer cardioprotection in short term use by older postmenopausal women. A re-analysis of the Women’s Health Initiative data found those randomised to oestrogen plus progestin had a two-fold increased risk of cardiovascular disease within the first two years of use compared to those using placebo. A possible cardioprotective effect was found in women who started therapy closer to menopause, but only after six years of use. “Most women...start hormone therapy soon after menopause and generally use it for less than six years,” the authors said. ...
VTE and hormone replacement
VENOUS thromboembolism (VTE) is an important component of the benefit-to-risk equation in the use of postmenopausal hormone replacement therapy (HRT). Practitioners and women are often more concerned about breast cancer than thromboembolic complications; however, thromboembolic events are one of the commonest significant side-effects of HRT. This article summarises the data on the HRT-related VTE risk and factors that influence it. Both observational and interventional trials have shown a significant increase in VTE risk among current HRT users. 1 The Women’s Health Initiative (WHI) included clinical trials designed to ...